PHI: “We aim to revolutionize the regenerative medicine market “

A year ago, Patrik Eschricht assumed the role of CEO at PHI, heralding the shift towards regenerative medicine and a commitment to enhancing shareholder value.

This transition was further underscored by the entry of private Swiss distributor and investment company Altium as a major shareholder.